The US Food and Drug Administration (FDA) has approved monoclonal antibodies that block CTLA-4 (ipilimumab), PD-1 (pembrolizumab and nivolumab), and PD-L1 (atezolizumab) for the treatment of melanoma, non-small-cell lung cancer, renal cell carcinoma, Hodgkin lymphoma and bladder cancer. This evidence concerns the gene CD274 and non-small cell lung carcinoma.